incretin comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2025-10-26. Where a claim depends on a specific study, the study is described rather than over-claimed.
Development has progressed through early- and mid-stage human studies in adults with obesity and with type 2 diabetes. Published phase 2 data reported reductions in body weight and improvements in glycemic markers over the treatment period. No regulatory agency has approved the compound for any indication, and it remains available only within controlled research settings. Whether benefits observed in trials translate into durable outcomes after treatment stops is not yet established.
Retatrutide is an investigational synthetic peptide that acts as an agonist at three distinct G protein-coupled receptors. It combines activity at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor within a single molecule. This multi-receptor profile distinguishes it from earlier incretin-based compounds that engage one or two of these pathways. Researchers designed the molecule to test whether simultaneous activation produces greater metabolic effects than single or dual agonism alone.
Clinical development has progressed through phase 2 trials in adults with obesity and type 2 diabetes, with phase 3 programs reported as ongoing. Reported outcomes include reductions in body weight and improvements in glycemic measures over defined treatment periods. Whether these effects translate into durable benefits after treatment ends remains an open question. Long-term safety data across broad populations are not yet complete, and regulatory decisions have not been announced.
Retatrutide is an investigational synthetic peptide engineered to activate three distinct hormone receptors within a single molecule. It targets the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor simultaneously. This triagonist design distinguishes it from earlier incretin-based compounds that act on one or two of these pathways. Structural modifications relative to native gut hormones extend its residence time in circulation. The molecule remains under clinical evaluation and is not approved for any indication.
Receptor activation produces downstream effects that differ by tissue. GLP-1 receptor signaling influences appetite regulation and insulin secretion in a glucose-dependent manner. GIP receptor activity contributes to metabolic handling of nutrients and may modulate adipose tissue. Glucagon receptor engagement raises energy expenditure and promotes hepatic lipid turnover, though the balance among these actions in humans is still being characterized. Preclinical models showed reductions in body weight and improved glycemic markers.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Not a small molecule |
| Receptor targets | GLP-1, GIP, glucagon | Triple agonist activity |
| Appearance | White to off-white powder | Lyophilized solid |
| Solubility | Soluble in water | Also in aqueous buffers |
| Storage | −20 °C or below | Protect from light and moisture |
Each receptor contributes a different physiological effect. Activation of the GLP-1 receptor slows gastric emptying and reduces appetite signaling in the brain. GIP receptor activity influences insulin secretion and lipid handling, while glucagon receptor stimulation raises energy use and fat oxidation. Combining these pathways is intended to produce weight loss beyond what single- or dual-receptor agonists achieve. Researchers attribute the observed potency to simultaneous engagement of all three targets, though the exact contribution of each receptor to overall effect remains under investigation.
Clinical development has advanced through phase 2 trials in adults with obesity and type 2 diabetes. Reported phase 2 results described substantial average weight reduction over roughly forty-eight weeks of weekly dosing. A phase 3 program is ongoing to confirm efficacy and assess long-term safety. Because the compound has not received regulatory approval, it is not available as a prescription product. Public discussion of retatrutide often conflates trial findings with marketed status, an important distinction when interpreting coverage of the topic.
Retatrutide is a synthetic peptide developed as a single molecule that activates three distinct hormone receptors: GLP-1, GIP, and glucagon. The compound carries the internal designation LY3437943 and was engineered by modifying the backbone of glucose-dependent insulinotropic polypeptide. Its sequence incorporates non-natural amino acids and a fatty acid side chain that extends circulation time. The triple-agonist design aims to combine appetite suppression, improved insulin response, and increased energy expenditure in one agent. Published reports describe it as an investigational product rather than an approved medicine.
Acting as a triple agonist, the molecule binds the GLP-1, GIP, and glucagon receptors. GLP-1 activity slows gastric emptying and dampens appetite, while GIP signaling contributes to insulin sensitivity and fat metabolism. Glucagon receptor engagement raises energy expenditure and encourages fat breakdown, although it can also elevate blood glucose. Combining three pathways is intended to yield larger weight reduction than single or dual agonists, and researchers continue to examine how the balance among them shapes tolerability.
Clinical studies have reported notable reductions in body weight among participants. Early trials measured safety and explored several dose levels, and later studies tracked body-weight change over months of treatment. Investigators also monitor effects on glycemic markers, liver fat, and blood lipids. Because the compound is still in development, questions about long-term safety, cardiovascular outcomes, and durability after treatment ends remain open.
Pharmacologically the compound activates three receptors: GLP-1, GIP, and glucagon. GLP-1 and GIP signaling contribute to glucose-dependent insulin release, delayed gastric emptying, and reduced appetite, while glucagon receptor activation is associated with increased energy expenditure and hepatic fat oxidation. The single-molecule design is intended to keep these activities in one peptide rather than combining separate agents. Relative activity at each receptor differs, and the balance between them is a central question in interpretation. The glucagon component is partly offset by incretin-mediated insulin secretion, an interaction that remains incompletely characterized.
Development has progressed from single- and multiple-ascending-dose studies in healthy volunteers into larger randomized trials in adults with obesity, type 2 diabetes, and fatty liver disease. Early reports describe dose-dependent reductions in body weight and improvements in glycemic markers over treatment periods of several months. Whether the glucagon arm adds tolerability cost without added benefit is still debated. Long-term cardiovascular outcomes, effects after treatment stops, and performance in older or comorbid populations are open questions rather than settled findings. Approval status may change, so the current investigational label should be confirmed against regulatory sources.
Retatrutide is an investigational synthetic peptide developed under the code LY3437943, with a backbone derived from glucose-dependent insulinotropic polypeptide. Several non-proteinogenic residues, including alpha-aminoisobutyric acid, appear in that backbone, and a fatty diacid side chain attached through a linker extends circulation time. The molecule carries roughly thirty-nine amino acid units and a total mass near 4.7 kilodaltons. Administration is by subcutaneous injection once weekly. Published work uses both the name retatrutide and the code LY3437943.
It is unnecessary to warn you not to allow the accession of any other, who is not a good Colombian, near Gamarra and La-Fuente, because it could happen that they would open their eyes about their political situation, and in truth, that if in that If there were a conversion of political ideas in the cabinet or currently a mutation of the government, everything would be lost. And what would our luck then be?"On the other hand, it has been pointed out that Bolívar, before his arrival in Peru, would have been conspiring against the Protectorate of San Martín, through Venezuelan agents such as Tomás de Heres (who participated in an attempted rebellion against Don José de San Martín in October 1821, being deported to Guayaquil and returning to Peru as an important adviser and general of the armies of the Venezuelan liberator), as well as requesting troops from Santander (vice president of Colombia) to generate uprisings and Peruvian protests through spies and infiltrators against San Martin. In this context, it would seem that Bolívar aspired to displace San Martín in the role of consecrating the Independence of South America, and also, to plunge Peru into anarchy that would benefit the interests, both personal of Bolívar to want to stand out as the most important caudillo for guarantee the law and order of the independence process at the continental level, as geopolitical of Gran Colombia, to obtain leadership at the continental level (and thus more easily concretize the future project of the Great Homeland) at the cost of sacrificing the interests of the Peruvians.
Minimally invasive surgery (also known as minimally invasive procedure) encompass surgical techniques that limit the size of incisions needed, thereby reducing wound healing time, associated pain, and risk of infection. Surgery by definition is invasive, and many operations requiring incisions of some size are referred to as open surgery. Incisions made during open surgery can sometimes leave large wounds that may be painful and take a long time to heal. Advancements in medical technologies have enabled the development and regular use of minimally invasive procedures. For example, endovascular aneurysm repair, a minimally invasive surgery, has become the most common method of repairing abdominal aortic aneurysms in the US as of 2003. The procedure involves much smaller incisions than the corresponding open surgery procedure of open aortic surgery. Interventional radiologists were the forerunners of minimally invasive procedures. Using imaging techniques, radiologists were able to direct interventional instruments through the body by way of catheters instead of the large incisions needed in traditional surgery. As a result, many conditions once requiring surgery can now be treated non-surgically. Diagnostic techniques that do not involve incisions, puncturing the skin, or the introduction of foreign objects or materials into the body are known as non-invasive procedures. Several treatment procedures are classified as non-invasive. A major example of a non-invasive alternative treatment to surgery is radiation therapy, also called radiotherapy.
=== Nutritional aspects === The bioavailability of protein from raw eggs (51%) is significantly lower than from cooked eggs (91%). Additionally, raw egg whites contain avidin, which inhibits the absorption of biotin. Consuming large amounts of raw egg white over long periods can potentially lead to biotin deficiency. Conversely, some research suggests egg white protein may help lower high cholesterol levels.
=== Partial drying === To achieve 0.6-0.84 water activity in food products, partial drying is employed for raw food that naturally have a high amount of humectants such as raisins, apricots, prunes and sultanas. Humectants are solutes (such as sugar or salt) that immobilize water in food. The drying process removes free water, and the humectants in the product bind the rest of the water, not allowing it to be utilized for chemical reactions or for microbial use.
== Mechanism of action == Two main ideas about how it might work have been proposed over the years. The first idea, which has been proven wrong, is that insulin makes cells more permeable, so that the chemotherapy drugs are absorbed faster into cells. The other idea is that insulin might cause the cells to start dividing, which makes them more susceptible to destruction of many cytotoxic chemotherapy drugs.
Sources: en.wikipedia.org
A testicular action was linked to circulating blood fractions – now understood to be a family of androgenic hormones – in the early work on castration and testicular transplantation in fowl by Arnold Adolph Berthold (1803–1861). Research on the action of testosterone received a brief boost in 1889, when the Harvard professor Charles-Édouard Brown-Séquard (1817–1894), then in Paris, self-injected subcutaneously a "rejuvenating elixir" consisting of an extract of dog and guinea pig testicle. He reported in The Lancet that his vigor and feeling of well-being were markedly restored but the effects were transient, and Brown-Séquard's hopes for the compound were dashed. Suffering the ridicule of his colleagues, he abandoned his work on the mechanisms and effects of androgens in human beings. In 1927, the University of Chicago's Professor of Physiologic Chemistry, Fred C. Koch, established easy access to a large source of bovine testicles – the Chicago stockyards – and recruited students willing to endure the tedious work of extracting their isolates. In that year, Koch and his student, Lemuel McGee, derived 20 mg of a substance from a supply of 40 pounds of bovine testicles that, when administered to castrated roosters, pigs and rats, re-masculinized them.
Following increased criticism by Colombian President Gustavo Petro over US strikes on vessels and support for Israel in the Gaza war during his visit to the September session of the UN General Assembly, the US Department of State revoked Petro's visa on 27 September, stating on X that: "Earlier today, Colombian president (Gustavo Petro) stood on a NYC street and urged US soldiers to disobey orders and incite violence." Petro stated that a US airstrike had killed a Colombian fisherman whose vessel was not involved in drug trafficking, and accused the US of murder. Trump responded calling Petro an "illegal drug leader", who was "low rated" and not helping diminish production of drugs, stating that the US would end the large subsidies it provided to Colombia. In October 2025, the United States Department of the Treasury announced sanctions against Petro and Interior Minister Armando Benedetti, citing their alleged involvement in illicit drug trafficking activities. These measures marked a significant deterioration in bilateral relations, with the Colombian government condemning the decision as politically motivated and labeling it "an act of aggression" against its sovereignty. Analysts described the move as one of the most severe diplomatic escalations between Bogotá and Washington in recent years.
== Self-replication == "Molecular assemblers" have been confused with self-replicating machines. To produce a practical quantity of a desired product, the nanoscale size of a typical science fiction universal molecular assembler requires an extremely large number of such devices. However, a single such theoretical molecular assembler might be programmed to self-replicate, constructing many copies of itself. This would allow an exponential rate of production. Then, after sufficient quantities of the molecular assemblers were available, they would then be re-programmed for production of the desired product. However, if self-replication of molecular assemblers were not restrained then it might lead to competition with naturally occurring organisms. This has been called ecophagy or the grey goo problem. One method of building molecular assemblers is to mimic evolutionary processes employed by biological systems. Biological evolution proceeds by random variation combined with culling of the less-successful variants and reproduction of the more-successful variants. Production of complex molecular assemblers might be evolved from simpler systems since "A complex system that works is invariably found to have evolved from a simple system that worked. . . . A complex system designed from scratch never works and can not be patched up to make it work. You have to start over, beginning with a system that works." However, most published safety guidelines include "recommendations against developing ... replicator designs which permit surviving mutation or undergoing evolution".
In April 2022, Collins embarked on her first live theatre tour, titled The GC's Big Night Out. Performing in venues across the UK, the seven-date tour was announced on 19 April 2021 and tickets went on sale on 23 April. The tour was originally scheduled to take place between 15–24 October 2021 but was postponed due to logistical issues surrounding the COVID-19 pandemic. The tour began in Manchester on 5 April 2022 and Collins was joined by Stephen Bailey who assumed the role of presenter. The show featured Collins singing, looking back at her life and career and being interviewed by Bailey before taking questions from the audience. She performed in Glasgow, Southampton, London, Birmingham and Cardiff before the tour concluded in Newcastle on 14 April. In May 2022, Collins was set to take over the role of Matron "Mama" Morton in the UK tour of the musical Chicago. Following the announcement of her casting in March, producer David Ian said "[They] were completely stunned by [Collins'] audition for the role" describing her as "an undeniable force both on and off stage" and that "audiences across the country [were] in for a treat." Collins received criticism from several actors and theatre fans on social media who described her as a "stunt casting". Responding to critics, Collins said she "auditioned for the role and trained really hard" adding that she "didn't just get it because of [her alter ego] the GC".
Sources: en.wikipedia.org
Retatrutide is an investigational synthetic peptide that activates three metabolic receptors: GLP-1, GIP, and glucagon. It is being studied for obesity and type 2 diabetes. It has not been approved for clinical use.
Earlier incretin therapies engage one or two receptors. Retatrutide adds glucagon receptor activity, which may raise energy expenditure. Whether this produces larger clinical benefits is still being tested.
It has completed phase 2 trials and moved into later-stage evaluation. No regulator has granted approval. Access outside research settings is not authorized.
It is a synthetic peptide triagonist that engages GIP, GLP-1, and glucagon receptors. Investigational compounds in this class are studied for metabolic conditions rather than for a single organ system.